Trials / Completed
CompletedNCT00087529
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 439 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS. The study will enroll approximately 435 subjects at up to 60 sites in the United States and Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | Intravenous repeating dose |
| DRUG | rituximab | Intravenous repeating dose |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2007-10-01
- First posted
- 2004-07-13
- Last updated
- 2015-09-09
- Results posted
- 2015-09-09
Source: ClinicalTrials.gov record NCT00087529. Inclusion in this directory is not an endorsement.